 Athira Pharmas stock has sold off some months ago on its Alzheimers drug candidate Fosgonimeton not meeting a primary endpoint in a randomized Phase 2 trial. The monotherapy arm did show remarkable efficacy, which appears stronger than 27 slowing of cognitive decline. 